These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2412034)

  • 1. Hemodynamic response to chronic ketanserin treatment in essential hypertension.
    Fagard R; Fiocchi R; Lijnen P; Staessen J; Amery A
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S128-9. PubMed ID: 2412034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension.
    Fagard R; Fiocchi R; Lijnen P; Staessen J; Moerman E; de Schaepdryver A; Amery A
    Br Heart J; 1984 Feb; 51(2):149-56. PubMed ID: 6362688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects on central haemodynamics and body fluid volumes of ketanserin in essential hypertension studies at rest and during dynamic exercise.
    Omvik P; Lund-Johansen P
    J Hypertens; 1983 Dec; 1(4):405-12. PubMed ID: 6681181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of ketanserin, a new antiserotonergic agent in the treatment of arterial hypertension.
    Ferrara LA; Fasano ML; Soro S; Rubba P; Iannuzzi A
    J Clin Pharmacol; 1985 Apr; 25(3):187-92. PubMed ID: 3158674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
    Ferrara LA; Fasano ML; Rubba P; Soro S; Marotta G; Mancini M
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S159-60. PubMed ID: 2412041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular profile and hypotensive mechanism of ketanserin in the rabbit.
    Bolt GR; Saxena PR
    Hypertension; 1985; 7(4):499-506. PubMed ID: 2861161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
    Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of ketanserin on blood pressure and biochemical parameters in treated patients with essential hypertension.
    Wing LM; Chalmers JP; West MJ; Bune AJ; Ayres B; Graham JR
    Clin Exp Hypertens A; 1984; 6(6):1107-17. PubMed ID: 6146414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responses of the systemic circulation and of the renin-angiotensin-aldosterone system to ketanserin at rest and exercise in normal man.
    Fagard R; Cattaert A; Lijnen P; Staessen J; Vanhees L; Moerman E; Amery A
    Clin Sci (Lond); 1984 Jan; 66(1):17-25. PubMed ID: 6690191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketanserin: haemodynamic effects and mechanism of action.
    Schalekamp MA; Woittiez AJ; Wenting GJ; van den Meiracker AH; Man in 't Veld AJ
    J Hypertens Suppl; 1986 Apr; 4(1):S7-12. PubMed ID: 2871144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of preeclamptic hypertension by ketanserin, a new serotonin receptor antagonist.
    Weiner CP; Socol ML; Vaisrub N
    Am J Obstet Gynecol; 1984 Jul; 149(5):496-500. PubMed ID: 6377898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
    J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moderate essential hypertension control: a double-blind crossover study between a serotonin antagonist and a post-synaptic alpha-blocker.
    Rosenthal J; Koehle W; Gruebel B; Fisher R
    J Hypertens Suppl; 1986 Apr; 4(1):S85-7. PubMed ID: 2871145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exercise performance in mildly hypertensive patients. Impairment by propranolol but not oxprenolol.
    Franciosa JA; Johnson SM; Tobian LJ
    Chest; 1980 Aug; 78(2):291-9. PubMed ID: 6995041
    [No Abstract]   [Full Text] [Related]  

  • 15. 5-HT2-receptor blockade in the treatment of heart failure. A preliminary study.
    Demoulin JC; Bertholet M; Soumagne D; David JL; Kulbertus HE
    Lancet; 1981 May; 1(8231):1186-8. PubMed ID: 6112531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemodynamic effects of ketanserin in the treatment of hypertension following CABG: a double-blind, placebo-controlled study.
    Vandenbroucke G; Foubert L; Evenepoel MC
    J Cardiothorac Anesth; 1989 Oct; 3(5 Suppl 1):3. PubMed ID: 2520966
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term hemodynamic effects of bunitrolol at rest and during exercise in essential hypertension.
    Lund-Johansen P
    J Cardiovasc Pharmacol; 1979; 1(1):77-83. PubMed ID: 94384
    [No Abstract]   [Full Text] [Related]  

  • 18. Antihypertensive therapy with ketanserin: metabolic and hemodynamic effects.
    Levinson PD; Zimlichman R; Goldstein DS; Keiser HR
    J Cardiovasc Pharmacol; 1988 Oct; 12(4):384-9. PubMed ID: 2465437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chronic antihypertensive treatment with ketanserin versus metoprolol on blood pressure and large arteries' compliance in humans: a cross-over double-blind study.
    De Luca N; Rosiello G; Crispino M; Volpe M; Galletti P; Buzzetti G; Trimarco B
    J Clin Pharmacol; 1988 Apr; 28(4):332-8. PubMed ID: 3292598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute and long-term effects of nitrendipine on resting and exercise hemodynamics in essential hypertension.
    Nannan ME; Melin JA; Vanbutsele RJ; Lavenne F; Detry JM
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1043-8. PubMed ID: 6085364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.